AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00634075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
Study NCT02129595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A placebo will given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
Study NCT02036697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 15 mcg
Study NCT01135420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Monitoring (TM) with Motivational Interviewing
Description: Patients in the TM condition will receive an in-person session while in the inpatient psychiatry program, followed by monitoring delivered over the telephone for three months after discharge. The TM intervention will have a motivational interviewing component to address patients' motivation to obtain help for and reduce their substance abuse. The purpose of the intervention condition is to monitor patients' substance use, facilitate patients' entry into outpatient substance use disorder (SUD) treatment, and encourage ongoing 12-step selfhelp group participation to support sobriety.
Study NCT01135420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: All patients in the trial will receive usual care (i.e., the care they would have received in the absence of a study).
Study NCT01354340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Limicol
Description: 3 tablets (Limicol) + 3 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
Study NCT01354340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Limicol
Description: 6 tablets (Limicol) / day during 1 month and follow-up 1 month without treatment
Study NCT03093948 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic post-conditioning
Description: Remote ischemic post-conditioning will undergo in both thighs at the beginning of targeted temperature management. This will be done with noninvasive measurement of blood pressure, with cuffs inflated to 200 mmHg for four 5 min cycles and interrupted three times for 5 min with cuff deflation.
Study NCT03948802 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Interleukine 33 test in blood plasma
Description: ELISA test for Interleukin 33
Study NCT00581048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural source d-α-tocopheryl acetate
Description: 1500 units daily for 16 weeks
Study NCT02820844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1358820
Description: GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). 10 mL of the drug will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
Study NCT02820844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1358820
Description: GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). 10 mL of the drug will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
Study NCT02820844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection is made up of sodium chloride (0.9 mg). 10 mL of the injection will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 cm apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
Study NCT02820844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Description: Subjects will use prophylactic antibiotic therapy approved for the indication of UTIs, at the discretion of the investigator, with the exception of those in the class of aminoglycosides. The therapy will begin 1 to 3 days prior to the administration of study treatment, and continue for 1 to 3 days following the treatment.
Study NCT02820844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antibiotic therapy
Description: Subjects will use prophylactic antibiotic therapy approved for the indication of UTIs, at the discretion of the investigator, with the exception of those in the class of aminoglycosides. The therapy will begin 1 to 3 days prior to the administration of study treatment, and continue for 1 to 3 days following the treatment.
Study NCT02820844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bladder diary
Description: The bladder diary is a self-reporting tool to record subject's data on micturition. Subjects will enter data in the diary over 3 consecutive days. During Screening, data will be collected within 28 days prior to first treatment. During treatment periods, data will be collected within a week prior to each scheduled visit. The bladder diary will capture the following information: 1) Date and time of urinary episode, 2) episodes of micturition, 3) episodes of urinary incontinence, 4) episodes of urgency, 5) intensity of urgency, 6) episodes of nocturia, 7) use of CIC, and 8) urine volume. Diary data will not be collected when a subject experiences symptoms of a UTI.
Study NCT02820844 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bladder diary
Description: The bladder diary is a self-reporting tool to record subject's data on micturition. Subjects will enter data in the diary over 3 consecutive days. During Screening, data will be collected within 28 days prior to first treatment. During treatment periods, data will be collected within a week prior to each scheduled visit. The bladder diary will capture the following information: 1) Date and time of urinary episode, 2) episodes of micturition, 3) episodes of urinary incontinence, 4) episodes of urgency, 5) intensity of urgency, 6) episodes of nocturia, 7) use of CIC, and 8) urine volume. Diary data will not be collected when a subject experiences symptoms of a UTI.
Study NCT02820844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: King's Health Questionnaire (KHQ)
Description: The KHQ will assess the impact of urinary incontinence on QOL. It is a questionnaire with 21 items and the following 9 domains: 1) General health, 2) Incontinence impact, 3) Role limitations, 4) Physical limitations, 5) Social limitations, 6) Personal relationships, 7) Emotion, 8) Sleep/energy, 9) Severity measure. The items are answered by subjects themselves, and scores are summated using a defined algorithm.
Study NCT02820844 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: King's Health Questionnaire (KHQ)
Description: The KHQ will assess the impact of urinary incontinence on QOL. It is a questionnaire with 21 items and the following 9 domains: 1) General health, 2) Incontinence impact, 3) Role limitations, 4) Physical limitations, 5) Social limitations, 6) Personal relationships, 7) Emotion, 8) Sleep/energy, 9) Severity measure. The items are answered by subjects themselves, and scores are summated using a defined algorithm.
Study NCT02820844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overactive Bladder Symptom Score (OABSS)
Description: The OABSS will comprehensively assess symptoms of OAB, such as frequency of micturition, nocturia, urinary urgency, and urge incontinence. It consists of 4 questions which will be responded by subjects themselves, by selecting the most appropriate answer for each question.
Study NCT02820844 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Overactive Bladder Symptom Score (OABSS)
Description: The OABSS will comprehensively assess symptoms of OAB, such as frequency of micturition, nocturia, urinary urgency, and urge incontinence. It consists of 4 questions which will be responded by subjects themselves, by selecting the most appropriate answer for each question.
Study NCT02820844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Benefit Scale (TBS)
Description: The TBS consists of one question (My condition has), to which the subject will answer by selecting one of the following responses: greatly improved, improved, not changed, worsened. The TBS will assess treatment benefit of GSK1358820.
Study NCT01354340 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
Study NCT00126191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Low Risk: Intravenously on Day 3 of the first cycle (One cycle is 14 days) then day 1 for next 2 cycles (Regimen A) High Risk: Regimen A followed by a 5-day cycle where rituximan is given on day 1
Study NCT00126191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Low Risk/High Risk: Intravenously on day 1 and day 2 of a 14-day cycle for 3 cycles (regimen A)
Study NCT02820844 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment Benefit Scale (TBS)
Description: The TBS consists of one question (My condition has), to which the subject will answer by selecting one of the following responses: greatly improved, improved, not changed, worsened. The TBS will assess treatment benefit of GSK1358820.
Study NCT02227030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB 722 CL solution
Study NCT02227030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB 722 CL tablet
Study NCT02227030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Study NCT02227030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Study NCT03045588 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined exercise and diet intervention
Description: Both groups exercise 6 times per week in 4 weeks conducted as 3 evening and 3 morning sessions per week. Both groups receive dietary products to be consumed immediately before and after each evening and morning session, respectively. One group conduct morning sessions in a fasted state, the other conduct the morning sessions in a fed state. Performance pre and post is measured, and muscle biopsies are obtained.
Study NCT03045588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined exercise and diet intervention
Description: Both groups exercise 6 times per week in 4 weeks conducted as 3 evening and 3 morning sessions per week. Both groups receive dietary products to be consumed immediately before and after each evening and morning session, respectively. One group conduct morning sessions in a fasted state, the other conduct the morning sessions in a fed state. Performance pre and post is measured, and muscle biopsies are obtained.
Study NCT01739608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invitation to screening
Description: Invitation to screening
Study NCT01739608 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invitation to screening
Description: Invitation to screening
Study NCT00792311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tsui test
Description: The stimulator is set at frequency of 1Hz with 200ms pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
Study NCT00466947 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection, 4 doses
Study NCT00466947 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix
Description: Intramuscular injection, 2 doses in Synflorix group and 3 doses in Control group
Study NCT00466947 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: Intramuscular injection, 2 doses in Synflorix group and 3 doses in Control group
Study NCT00466947 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Intramuscular injection, 3 doses
Study NCT00466947 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection,3 doses
Study NCT01525303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Treatment for Chronic Headache- Exercise Version
Description: This behavioral treatment program consists of behavioral approaches to headache management: progressive muscle relaxation, stress-management training, and biofeedback. Skills for these techniques are presented during the clinic sessions, and supplemented with workbooks and audio CDs. In addition, all participants will receive a graduated exercise prescription of 20-30 minutes of moderate-intensity exercise, five days per week. They will be instructed to assess the intensity of their exercise using the Borg perceived exertion scale. Client contact sessions are as follows: Clinic Session (CS)1; Phone Session (PS) 1 (end of week1), CS 2 (end of week 4); PS 2 (end of week 6); CS 3 (end of week 8).
Study NCT01976169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991 and T-DM1
Description: The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.~A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.~Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)
Study NCT00466947 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' DTPa-IPV/Hib vaccine
Description: Intramuscular injection, 1 dose in Synflorix group and 4 doses in Control group
Study NCT00466947 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' DTPa-IPV/Hib vaccine
Description: Intramuscular injection, 1 dose in Synflorix group and 4 doses in Control group
Study NCT01822769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary rehabilitation
Description: See Arm Description
Study NCT01822769 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: See Arm Description
Study NCT03684837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamine D supplementation
Description: a vitamine D dose for week
Study NCT03684837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chronic exercise in whole body vibration (WBV)
Description: exercise in WBV during 03 months, e times per week
Study NCT03684837 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: chronic exercise in whole body vibration (WBV)
Description: exercise in WBV during 03 months, e times per week
Study NCT04791657 — intervention group
Intervention type: PROCEDURE
Intervention: Appendectomy
Description: Surgical treatment for appendicitis
Study NCT00383331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: A: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles~B: 500 mg/m2, intravenous (IV), every 14 days x 9 cycles
Study NCT00383331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: A: 1250 mg/m2, intravenous (IV) days 1 and 8, every 21 days x 6 cycles~B: 1500 mg/m2, intravenous (IV), every 14 days x 9 cycles
Study NCT00130104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transthecal Metacarpal Block
Study NCT00804895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALTIM, cortivazol injections
Description: ALTIM, cortivazol in greater occipital nerve injection separated by 2 or 3 days each.
Study NCT00804895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PROAMP, subcutaneous serum physiological saline
Description: Three injections will be performed at the level of the greater occipital nerve with a suboccipital approach. Injection will be separated by two or three days each.
Study NCT00804895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: standard prophylactic treatment
Study NCT00804895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Verapamil
Description: standard prophylactic treatment
Study NCT03024112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated humified high-flow nasal cannula Oxygen
Study NCT03024112 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen therapy
Study NCT02951234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVIG only
Description: All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin.
Study NCT02951234 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IVIG and Aspirin
Description: All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside.
Study NCT00422188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection
Description: Administered via intralipomal injection.
Study NCT00422188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via intralipomal injection.
Study NCT01939522 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Study NCT03380507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple therapy group
Description: Refer to arms description
Study NCT01960426 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of drug (Adalimumab/Infliximab)
Description: Measurement of drug (adalimumab/infliximab) and ADAs in the presence of drug.
Study NCT01960426 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensify treatment with the existing drug
Description: Intensify treatment with the existing drug and if this fails empirically switch to another TNF antagonist
Study NCT03924648 — intervention group
Intervention type: OTHER
Intervention: Endocan levels
Description: Venous blood sample from the antecubital veins for measuring serum concentration of Endocan. The serum endocan level was measured using a commercially available ELISA kit, which is produced to detect human endocan levels with high sensitivity and specificity (Elabscience Biotechnology Inc., Houston, TX, USA). The endocan measurements were performed in accordance with company's protocol.
Study NCT01742091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546 - SC
Description: Administered SC
Study NCT01742091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546 - IV
Description: Administered IV
Study NCT03086616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)
Description: Nal-IRI will be given directly into the tumor using CED.
Study NCT01540786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High resolution urodynamic assessment
Study NCT01540786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional urodynamic assessment
Study NCT03472820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Recommendations
Description: Specific dietary guidelines will be outlined for participants.
Study NCT01742091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - SC
Description: Administered SC
Study NCT01742091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SC
Description: Administered SC
Study NCT01742091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - IV
Description: Administered IV
Study NCT01742091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - IV
Description: Administered IV
Study NCT03472820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle Recommendations
Description: Participants are encouraged to average a minimum of 7 hours of sleep per night.
Study NCT02333669 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT00484276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
Study NCT03219801 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: SLE patients in the treated group were given human umbilical cord derived mesenchymal stem cells by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1, 3 and 6months were evaluated respectively the curative effect.
Study NCT03669406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autograft fat
Description: autograft fat